Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient setting DECNUPAZ marks AbbVies first ADC approved for blood cancer NORTH CHICAGO, Ill., May 27, 2026 /PRNewswire/ Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks To view or add a comment, sign in We've achieved 82% stable disease per RECIST, with 9 of 11 evaluable patients achieving stable disease, including one patient maintaining stable disease for over 15 months and another for 12 months
10.1016/j.bbrc.2015.12.083 Biochem Biophys Res Commun
10.1016/j.tifs.2020.08.006 Trends Food Sci
Both Grx catalyze the deglutathionylation of protein targets in two steps
This synthetic pentapeptide is thought to operate in a manner akin to Growth Hormone Releasing Peptides (GHRPs) and may simulate the natural action of the hunger hormone, ghrelin
US$ 21.07
US$ 23.21
US$ 23.58
US$ 26.10
